Quick Answer
ASCENTAGE PHARMA GROUP INTERNATIONAL reported Research And Development Expense of $947.25 million for the year ending 2024.
- ASCENTAGE PHARMA GROUP INTERNATIONAL showed an increase of +34.0% in Research And Development Expense from 2023 to 2024.
- This data is from ASCENTAGE PHARMA GROUP INTERNATIONAL's annual report (Form 10-K), filed with the SEC on April 16, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2022 to 2024), ASCENTAGE PHARMA GROUP INTERNATIONAL's Research And Development Expense has grown by 27.5%.
- Historical annual values: Fiscal year 2024: $947.25 million | Fiscal year 2023: $706.97 million | Fiscal year 2022: $743.10 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: